LPCN - リポシン (Lipocine Inc.)

LPCNのニュース

   Lipocine to Participate in HC Wainwright Annual Global Investment Conference  2020/09/08 12:00:00 PR Newswire
SALT LAKE CITY, Sept. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it will provide a corporate update at the 22nd HC Wainwright Annual Global Investment Conference. The…
   Thinking about buying stock in UnitedHealth, VBI Vaccines Inc, ADMA Biologics, Qutoutiao, or Lipocine Inc?  2020/08/28 13:31:00 PR Newswire
NEW YORK, Aug. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UNH, VBIV, ADMA, QTT, and LPCN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The Daily Biotech Pulse: Modrerna Japanese Vaccine Deal Talk, Lipocine FDA Decision, Liver Congress Presentations  2020/08/28 08:17:00 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 27) Abbott Laboratories (NYSE: ABT)( announced emergency use authorization for an affordable …
   Thinking about buying stock in Northern Dynasty Minerals, Fluent Inc, Lipocine Inc, NetApp Inc., or HP?  2020/08/27 13:31:00 PR Newswire
NEW YORK, Aug. 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAK, FLNT, LPCN, NTAP, and HPQ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   64 Biggest Movers From Yesterday  2020/08/27 09:04:18 Benzinga
Gainers BigCommerce Holdings, Inc. (NASDAQ: BIGC ) shares gained 33.5% to close at $139.00 on continued momentum after the company announced a partnership with Facebook. Fluent, Inc. (NASDAQ: FLNT ) gained 31.9% to close at $3.02. Canaccord Genuity initiated coverage on Fluent with a Buy rating and announced a price target of $5. Fluidigm Corporation (NASDAQ: FLDM ) shares jumped 30% to close at $11.43 on Wednesday after the company announced it has received emergency use authorization from the FDA for the Advanta Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from COVID-19. SCWorx Corp. (NASDAQ: WORX ) shares climbed 29.8% to close at $2.1150 on Wednesday after surging over 12% on Tuesday. SCWorx, earlier during the month, appointed Timothy Hannibal as President, COO and Director. Li Auto Inc. (NASDAQ: LI ) shares rose 28.3% to close at $23.38. Li Auto generated $1.1 billion through its IPO last month. Cryoport, Inc. (NASDAQ: CYRX ) shares gained 27.9% to close at $51.51.
   Lipocine Announces Second Quarter 2020 Financial and Operational Results  2020/08/06 12:00:00 PR Newswire
SALT LAKE CITY, Aug. 6, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update. Second Quarter…
   Lipocine Announces Publication of LPCN 1144 Liver Fat Study ("LFS") Results  2020/08/03 12:00:00 PR Newswire
SALT LAKE CITY, Aug. 3, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer reviewed publication of LPCN 144 Liver Fat Study ("LFS") results, "LPCN 1144 Resolves Non-Alcoholic…
   Lipocine Announces Derivative Suit Was Dismissed  2020/07/31 12:00:00 PR Newswire
SALT LAKE CITY, July 31, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Wajda v. Patel, et al., Case: 2019-0122-JTL, a putative shareholder derivative action, was dismissed by…
   Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement  2020/07/13 12:00:00 PR Newswire
SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC ("Nasdaq") on July 9, 2020 indicating that…
   Lipocine Announces Presentations on TLANDO™ at AUA Virtual Experience 2020  2020/05/15 12:00:00 PR Newswire
SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the American Urological Association…
   Lipocine Announces Presentations on TLANDO™ at AUA Virtual Experience 2020  2020/05/15 12:00:00 PR Newswire
SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the American Urological Association…
   Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model  2020/05/13 12:00:00 PR Newswire
SALT LAKE CITY, May 13, 2020 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of a pre-clinical study of LPCN 1144. LPCN 1144 is an oral prodrug of bioidentical testosterone…
   Lipocine Announces First Quarter 2020 Financial and Operational Results  2020/05/07 12:00:00 PR Newswire
SALT LAKE CITY, May 7, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update. First Quarter…
   FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial  2020/05/05 12:00:00 PR Newswire
SALT LAKE CITY, May 5, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food & Drug Administration ("FDA") has accepted the Company's Investigational New Drug…
   U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition  2020/04/17 12:00:00 PR Newswire
SALT LAKE CITY, April 17, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United States Food and Drug Administration ("FDA") denied the Citizen Petition filed by Clarus…

calendar